Lucid Capital Markets analyst Alex Nowak initiates coverage on Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) with a Buy rating and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage